I was paid my full salary for 20 years despite doing no work - now I'm suing my employer
However, when this happened to Frenchwoman Laurence Van Wassenhove, she says it became a psychological nightmare - and now she is taking legal action against her employer for 'forced inactivity' and 'making her invisible' in the workplace.
The 59-year-old is suing one of Europe's biggest telecom companies, Orange, for discrimination, after alleging that she was left in a role with no tasks, no responsibilities, and no human connection for over 20 years.
The mother-of-two was full of ambition when she joined France Télécom, now known as Orange, back in 1993 - but after developing epilepsy and hemiplegia, which is a paralysis that only affects one side of the body, she could not work.
Due to her medical issues, Laurence, who is a trained HR assistant, was transferred to a more sedentary secretarial role.
However what seemed like a reasonable adjustment, quickly unravelled into a two-decade professional limbo.
In 2002, shortly after the transition from France Télécom to Orange, she claimed to have submitted a request to be transferred to another region in France.
However, an occupational health assessment later determined she was unfit for the role, and she was subsequently placed on standby.
Laurence, who is mother of an autistic child, said despite being paid her salary, it did not save her from facing eviction notices and struggling to make ends meet.
Speaking to FTV, Laurence claimed she felt like an 'outcast secretary' which took an emotional toll on her mental health.
'I was paid, yes,' she later told French media outlet Mediapart, 'but I was treated like I didn't exist.'
She claimed the company put her on standby, then sick leave, before presenting the option of retirement as a result of her disability.
Laurence was in professional limbo for 20 years and she claimed the inactivity led to severe depression.
Her lawsuit accuses Orange of failing in their legal duty to accommodate her health needs and provide meaningful work, which is a requirement under French labour law.
Under French labour law, employers are required to make a genuine effort to find an alternative position for employees who are deemed medically unfit to continue in their original roles.
She claims that despite repeated requests for training, redeployment, or support, she remained in a state of 'forced inactivity'.
Laurence claimed that not much improved even after a complaint to the government and High Authority for the Fight against Discrimination back in 2015.
Speaking to FTV, she added: 'Being paid, at home, not working is not a privilege. It's very hard to bear.'
Her lawyer David Nabet-Martin argues that Orange failed in its obligation to provide reasonable workplace accommodations, and that this long-term sidelining constitutes discrimination under French labour law.
Orange told French outlet La Dépêche that the company had taken Laurence's 'personal social situation' into account and ensured she was kept in the best possible conditions during her time away from active duties.
The telecoms giant also claimed she had been considered for a return to work in a new role, though this never materialised, as she was frequently on sick leave at the time.
FEMAIL has reached out to Orange for further comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
9 minutes ago
- The Independent
Century-old pair of lungs stored in jar reveals how 1918 Spanish flu pandemic began
A pair of lungs preserved over a century ago from a deceased Spanish flu patient has helped unravel the genetic adaptations undergone by the virus to spread across Europe during the start of the 1918 pandemic. The Spanish flu pandemic of 1918-1920 was one of the most devastating pandemics in history, claiming some 20 to 100 million lives worldwide. However, little is known about how the flu virus mutated and adapted throughout the pandemic. Understanding how viruses evolved during past pandemics remains crucial for developing targeted countermeasures for the future, researchers say. Scientists have now reconstructed the first Swiss genome of the influenza virus behind the 1918 pandemic, helping unravel how it spread across Europe during its initial waves of infections. Researchers used an over 100-year-old virus sample taken from a formalin-fixed lung specimen in the Medical Collection of Switzerland's University of Zurich. The virus sample was taken from an 18-year-old patient from Zurich who died during the first wave of the pandemic in Switzerland and underwent an autopsy in July 1918. 'This is the first time we've had access to an influenza genome from the 1918–1920 pandemic in Switzerland. It opens up new insights into the dynamics of how the virus adapted in Europe at the start of the pandemic,' said Verena Schünemann, a co-author of the study from the University of Zurich. Researchers compared the Swiss genome with versions previously published from Germany and North America to find that the Swiss strain already carried three key adaptations to infect and spread among humans that would persist in the virus until the end of the pandemic. Two of these mutations seem to have made the virus more resistant to the human immune system, an important barrier against the transmission of such flu viruses originating from animals. Another mutation of a protein in the virus's membrane improved its ability to bind to entry point receptors in human cells, making it more resilient and infectious. In the study, scientists used a new method with improved ability to recover ancient RNA fragments from specimens. 'Medical collections are an invaluable archive for reconstructing ancient RNA virus genomes. However, the potential of these specimens remains underused,' said Frank Rühli, another author of the study. Researchers hope future studies using the method could lead to a better understanding of how viruses adapt to humans during a pandemic, enabling us to better anticipate and adapt to future pandemics.
Telegraph
41 minutes ago
- Telegraph
Prostate cancer breakthrough cuts risk of erectile dysfunction
Men having prostate cancer treatment could be spared erectile dysfunction thanks to a breakthrough. The ERECT trial, investigating methods to preserve erectile function in men undergoing treatment, treated them using MRI-guided radiotherapy. This method targets the prostate while avoiding the nerves and blood vessels needed for erections. Erectile dysfunction is one of the most common side-effects of prostate cancer treatment, especially following radiotherapy or surgery. Treatments can affect the nerves and blood vessels involved in achieving and maintaining an erection, leading to varying degrees of sexual dysfunction in many patients. The study, by University Medical Centre Utrecht, found the targeted method had less than half the risk of erectile dysfunction compared with standard techniques. In the UK, prostate cancer is the most common cancer in men. Each year, approximately 55,000 men are diagnosed with it and, despite advances in detection and treatment, around 12,000 die from the disease annually with around 10,000 deaths a year in England. The incidence of prostate cancer has been rising, partly because of increased awareness and PSA testing. However, survival rates have also improved significantly. Nearly 80 per cent of men diagnosed with prostate cancer today are expected to survive for at least 10 years. The Telegraph is campaigning for the introduction of targeted screening for prostate cancer. Health advisers are currently considering the evidence for rolling out screening that could target tests to those at increased risk of the disease, such as black men or those with a family history of the disease. However, getting the focus right is crucial. Too many false positives can lead to over treatment of slow-growing disease, which can mean needless potentially distressing side-effects. Dr Jochem van der Voort van Zyp, the lead investigator, said: 'With MRI guidance, we limit radiation to erectile tissues but still treat the prostate effectively. With the enhanced precision of MRI guidance, we gain the confidence to limit the dose these erectile tissues receive. 'The prostate gets the therapeutic dose while the erectile tissues receive a much lower dose, thus preserving their function.' The trial of 70 men found that, at six months, six per cent had erectile dysfunction, compared to 21 per cent with conventional treatment. After 18 months, 16 per cent experienced dysfunction compared to 36 per cent in the control group. Experts said the new technique could offer men a better chance of maintaining sexual function following prostate cancer treatment without compromising cancer control. It is estimated that more than 16,000 men a year – those with low to intermediate risk disease – who receive radiotherapy could potentially benefit from such advances. So far, the technology is being used at the The Royal Marsden NHS Foundation Trust and The Christie NHS Foundation Trust in Manchester, with plans for rollout to two more sites. The device used, the Elekta Unity MR-Linac, combines MRI with radiation delivery for precise treatment. It allows doctors to see the prostate and surrounding tissues in detail and adjust treatment in real-time to avoid damaging healthy structures. John Christodouleas, Elekta's senior vice president of medical affairs, said: 'These results add to growing evidence that minimising radiation to normal tissues improves quality of life for men with prostate cancer.' Elekta Unity MR-Linac is the world's first and only device to combine a high-field MRI with a state-of-the-art linear accelerator. Experts said that enabled clinicians to use imaging to guide radiation delivery to tumour targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If, for example, if the prostate shifts because of motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues. The preliminary results were presented by clinicians from University Medical Centre Utrecht at the European Society for Radiotherapy and Oncology annual congress earlier this year.
Daily Mail
2 hours ago
- Daily Mail
Kenny Logan bravely reveals his sex life struggles with wife Gabby (and what he keeps private in the bedroom) after he had his prostate removed following cancer battle
Kenny Logan has bravely revealed his sex life struggles with wife Gabby to raise awareness for men who have also had their prostate removed. Former Scottish rugby international Kenny, 53, was diagnosed with cancer in February 2022 after Gabby, 52, urged him to go to the doctors. In a candid chat with the Telegraph, Kenny shared erections became 'impossible' during his cancer battle which he feared would take a toll on their sex life. He said: 'I was forewarned that prostatectomy meant that, at least for a while, getting erections would be impossible. That's a huge deal for any man.' 'I never allowed myself to stress "what if they never come back". Instead, I focused on being fit and cancer-free, I'm relentlessly positive. After about three months, I was relieved to have some movement down there. 'When it came to sex, things were 'inconsistent' let's say, for a good three months [after that].' Kenny also explained he used a 'penis pump' to to stimulate an erection, which he insists on keeping private in the bedroom. Vacuum pumps encourage blood to flow to the penis, causing an erection. They work for most men and can be used if medicine is not suitable or does not work, as per the NHS. He said: 'It's certainly not sexy... I used it for 10 minutes a day or so, several times in that first month, grateful Gabby was away working on the Commonwealth Games. 'I warned her that if she ever walked in on me using it and didn't back straight out the door, I'd never speak to her again! Some things are private, even in marriage.' Kenny and presenter Gabby have been married for over 22 years and share two children together. In February 2023, Kenny spoke candidly about the after-effects of treatment, and said they left him 'black and blue downstairs'. Speaking to The Telegraph at the time, he said: 'Whether it be my dyslexia, my relationship, IVF, we've always been quite open. So, I was quite happy to talk about erectile dysfunction and all these other things because I was like, "It is a symptom".' 'From a sexual point of view, it's not consistent. As the surgeon said to me, this could take 18 months. 'Within a month, I was getting movement, where he says, "That's amazing". So it's just not as consistent. The beauty is you can take a tablet and it changes things.' He explained that his brave honesty was motivated by his desire to help other people. Reiterating the need for all men his age to get checked, he said: 'If I can help one person, that'd be great. But I've probably helped a lot of people with the coverage it had.' The couple said Kenny was 'extremely lucky' they caught it early, which afforded him options regarding treatment. Kenny was inspired to go for a general check up after hearing guests on his wife's podcast discuss having their hormones tested. And when he did his results showed a high level of PSA - prostate-specific antigen. 'I got checked and very quickly, within three to four months, I had a biopsy and they said there was something there but they'd keep an eye on it,' he said. He said what stood out the most from that appointment was the specialist telling him '40 per cent of [his] mates have got this [high PSA levels] but don't know'. It doesn't always lead to cancer and many men go their entire lives not knowing. So when he was diagnosed with prostate cancer a short time later, Kenny recalled it being 'a huge shock'. He made the decision to remove the prostate entirely and is now three months post operation feeling almost as good as new. 'I'm probably about 90 per cent back to normal,' he said. Prostate cancer can often be treated if caught early, but symptoms usually do not show up until the cancer is already in advanced states. It is the most common cancer in men in the UK. The couple are encouraging men to learn more about the disease and consider talking to their GP about the risks. Every year, upwards of 52,300 men are diagnosed with prostate cancer in the UK - more than 140 every day. Up to 11,800 men in Britain die from prostate cancer annually, meaning it trails only lung and bowel cancer in yearly fatalities. WHAT IS PROSTATE CANCER? How many people does it kill? More than 11,800 men a year - or one every 45 minutes - are killed by the disease in Britain, compared with about 11,400 women dying of breast cancer. It means prostate cancer is behind only lung and bowel in terms of how many people it kills in Britain. In the US, the disease kills 26,000 men each year. Despite this, it receives less than half the research funding of breast cancer and treatments for the disease are trailing at least a decade behind. How many men are diagnosed annually? Every year, upwards of 52,300 men are diagnosed with prostate cancer in the UK - more than 140 every day. How quickly does it develop? Prostate cancer usually develops slowly, so there may be no signs someone has it for many years, according to the NHS. If the cancer is at an early stage and not causing symptoms, a policy of 'watchful waiting' or 'active surveillance' may be adopted. Some patients can be cured if the disease is treated in the early stages. But if it is diagnosed at a later stage, when it has spread, then it becomes terminal and treatment revolves around relieving symptoms. Thousands of men are put off seeking a diagnosis because of the known side effects from treatment, including erectile dysfunction. Tests and treatment Tests for prostate cancer are haphazard, with accurate tools only just beginning to emerge. There is no national prostate screening programme as for years the tests have been too inaccurate. Doctors struggle to distinguish between aggressive and less serious tumours, making it hard to decide on treatment. Men over 50 are eligible for a 'PSA' blood test which gives doctors a rough idea of whether a patient is at risk. But it is unreliable. Patients who get a positive result are usually given a biopsy which is also not fool-proof. Scientists are unsure as to what causes prostate cancer, but age, obesity and a lack of exercise are known risks. Anyone with any concerns can speak to Prostate Cancer UK's specialist nurses on 0800 074 8383 or visit
